Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
Top Page
Lepu Biopharma Co. Ltd. Class H
(2157)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$4.50
▼(-9.64% Downside)
Action:ReiteratedDate:11/22/25
The overall stock score is primarily influenced by the company's weak financial performance, characterized by negative profitability and high leverage. Technical analysis further supports a bearish outlook, with the stock trading below key moving averages and showing oversold conditions. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield, making the stock less attractive to investors.
Positive Factors
Revenue Growth
Very strong reported revenue growth indicates rapid top-line expansion and accelerating market adoption of products. Sustained high revenue growth over 2-6 months supports scale advantages, broader customer reach, and greater potential to fund R&D and commercialization investments.
Negative Factors
Persistent Unprofitability
Consistent negative net income and negative EBIT/EBITDA margins show the company is not generating operating profits. Over months this reduces retained earnings, limits reinvestment capacity, and increases reliance on external funding unless operating efficiency materially improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Very strong reported revenue growth indicates rapid top-line expansion and accelerating market adoption of products. Sustained high revenue growth over 2-6 months supports scale advantages, broader customer reach, and greater potential to fund R&D and commercialization investments.
Read all positive factors
Lepu Biopharma Co. Ltd. Class H (2157) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.36B
Dividend YieldN/A
Average Volume (3M)13.90M
Price to Earnings (P/E)30.8
Beta (1Y)0.94
Revenue Growth240.05%
EPS Growth-140.09%
CountryHK
Employees498
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.13
Shares Outstanding1,804,439,800
10 Day Avg. Volume11,565,494
30 Day Avg. Volume13,902,953
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.92
Price to Sales (P/S)11.31
P/FCF Ratio-16.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$1.20B
Lepu Biopharma Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugat...
How the Company Makes Money
Lepu Biopharma generates revenue primarily through the sale of its biopharmaceutical products, including proprietary drugs and biosimilars, which are marketed to hospitals and healthcare providers. The company also earns income from licensing agre...
Lepu Biopharma Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 700.45M | 367.79M | 225.35M | 15.57M | 0.00 | 0.00 |
| Gross Profit | 619.27M | 292.97M | 197.07M | 13.57M | 0.00 | 0.00 |
| EBITDA | -72.37M | -311.94M | 86.95M | -596.53M | -865.23M | -383.76M |
| Net Income | -177.20M | -411.38M | -22.10M | -689.05M | -1.01B | -581.85M |
Balance Sheet | ||||||
| Total Assets | 2.36B | 2.28B | 2.38B | 2.53B | 2.08B | 2.42B |
| Cash, Cash Equivalents and Short-Term Investments | 536.34M | 464.91M | 489.64M | 678.20M | 205.17M | 761.40M |
| Total Debt | 917.81M | 850.16M | 746.82M | 690.30M | 335.26M | 203.08M |
| Total Liabilities | 1.65B | 1.60B | 1.50B | 1.63B | 1.23B | 921.89M |
| Stockholders Equity | 745.26M | 702.83M | 896.90M | 900.76M | 836.71M | 1.47B |
Cash Flow | ||||||
| Free Cash Flow | -102.02M | -258.14M | -292.04M | -591.38M | -835.12M | -724.51M |
| Operating Cash Flow | -81.26M | -196.39M | -250.84M | -480.93M | -621.74M | -422.69M |
| Investing Cash Flow | -38.13M | -61.75M | 18.26M | -74.66M | -3.89M | -749.67M |
| Financing Cash Flow | 0.00 | 232.08M | -11.01M | 1.03B | 380.31M | 1.39B |
Lepu Biopharma Co. Ltd. Class H Technical Analysis
Positive
4.98
Price Trends
4.84
Positive
5.22
Positive
6.28
Negative
Market Momentum
0.23
Negative
70.99
Negative
80.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2157, the sentiment is Positive. The current price of 4.98 is below the 20-day moving average (MA) of 4.99, above the 50-day MA of 4.84, and below the 200-day MA of 6.28, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 70.99 is Negative, neither overbought nor oversold. The STOCH value of 80.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2157.
Lepu Biopharma Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$24.33B | 42.36 | 15.32% | ― | 48.38% | ― | |
54 Neutral | HK$17.98B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$10.79B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$4.25B | -10.14 | -32.79% | ― | 29639.67% | 23.30% | |
41 Neutral | HK$18.81B | -25.84 | -9.08% | ― | 964.40% | 65.90% | |
40 Underperform | HK$11.36B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.11
2.01
49.02%
HK:1672
Ascletis Pharma, Inc.
16.94
9.28
121.15%
HK:2162
Keymed Biosciences, Inc.
67.00
18.90
39.29%
HK:2171
CARsgen Therapeutics Holdings Ltd.
18.67
3.51
23.15%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
59.55
44.29
290.24%
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
5.20
-1.71
-24.75%
Lepu Biopharma Co. Ltd. Class H Corporate Events
Lepu Biopharma Secures Upfront Payment and Sets Royalty Terms in Excalipoint Licensing Deal
Dec 18, 2025
Lepu Biopharma has confirmed that all conditions precedent under its Share Purchase Agreement with Excalipoint have been satisfied and that it has received the first tranche of upfront payment under their Intellectual Property Assignment and Licen...
Lepu Biopharma Shareholders Approve RSU Scheme and Share Mandate at 2025 EGM
Dec 18, 2025
Lepu Biopharma Co., Ltd. reported that its 2025 second extraordinary general meeting, held in Beijing on December 18, 2025, was duly convened in compliance with PRC laws and the company’s Articles of Association, with all resolutions passed ...
Lepu Biopharma Updates Articles of Association Following H Shares Issuance
Dec 2, 2025
Lepu Biopharma Co., Ltd. has announced amendments to its Articles of Association following the issuance of new H Shares, as approved by the China Securities Regulatory Commission. This move, which increases the company’s registered capital, ...
Lepu Biopharma to Discuss RSU Scheme at 2025 EGM
Nov 28, 2025
Lepu Biopharma Co., Ltd. has announced the convening of its Second 2025 Extraordinary General Meeting (EGM) to discuss and potentially approve a series of resolutions related to its Restricted Share Unit (RSU) Scheme. The resolutions include the a...
Lepu Biopharma Enters New Procurement Agreement with Lepu Medical
Nov 28, 2025
Lepu Biopharma Co., Ltd. has entered into a New Procurement Framework Agreement with Lepu Medical to continue their ongoing transactions, which include the supply of raw materials and services for clinical trials and employee welfare. This agreeme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.